Taneesa Williamson Regenerative breast implants may soon be a reality.
The global breast implant market is currently estimated to be worth $3 billion USD, with breast reconstruction and augmentation procedures ranking as the second most common plastic surgery performed worldwide. While the majority of these procedures rely on synthetic silicone implants, they can come with associated risks related to the body’s reaction to foreign materials.
However, a groundbreaking advancement is set to reshape the landscape of reconstructive and aesthetic breast procedures: CollPlant Biotechnologies and Stratasys Ltd. have initiated a pre-clinical study on next-generation, regenerative breast implants.
These 200cc commercial implants are produced on a Stratasys’ Origin 3D printer, marking a significant departure from traditional silicone implants. What makes these new implants revolutionary is their ability to regenerate natural breast tissue, offering an alternative that closely mimics the body’s natural processes. The implants are designed to gradually integrate into the body, encouraging tissue regeneration and reducing the likelihood of immune responses or complications associated with synthetic materials. According to Collplant, the implants in development are bioprinted and loaded with compositions that are based on rhCollagen, autologous fat cells and ECM components.
Not only does it promise a potentially safer and more natural alternative to silicone implants, but it also opens up new possibilities for customisation. Since the implants are 3D-printed, they can be tailored to fit the patient’s body more precisely, reducing the need for future corrective surgeries or adjustments.
This innovation could significantly reduce the risks associated with traditional implants, such as capsular contracture, rupture, or leakage, all while fostering a more natural appearance and feel. For breast cancer survivors or individuals seeking augmentation, the advent of regenerative breast implants is poised to change the narrative, providing a solution that blends cutting-edge technology with the body’s own healing capabilities.
As CollPlant Biotechnologies and Stratasys continue their pre-clinical trials, the medical community and prospective patients alike are watching closely. If successful, this collaboration could transform the future of breast reconstruction and aesthetic surgery, ushering in a new era where synthetic materials give way to regenerative, natural solutions that redefine what’s possible in modern medicine.
Read our latest issue below:
There are 5 ways you can catch up with SPA+CLINIC
- Our quarterly print magazine, delivered to your door. Subscribe here.
- Our website, which is updated daily with its own completely unique content and breaking news.
- Our weekly newsletter – free to your inbox! Subscribe here.
- Our digital magazine – click here to view previous issues.
- Our social media – see daily updates on our Instagram, Facebook & Linkedin
